IKC profitability and capital allocation support earnings growth, but dialysis volume remains constrained by mortality and insurance headwinds.
| Quarter | Q4 FY25 |
|---|---|
| Call date | 2026-02-03 |
| Length | 44 minutes |
| EPS | $3.40 |
| EPS consensus | $3.24 |
| Revenue | $3.6B |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
All DVA earnings ยท Back to DVA overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.